The innovative nuclear medicine GPN01530-2, which targets FAP (Fibroblast Activation Protein) and was independently developed by Grand Pharma, has recently been accorded Fast Track designation by the U.S. Food and Drug Administration (FDA). Prior to this, the drug had already secured FDA clearance to commence Phase I/II clinical trials aimed at diagnosing solid tumors. The granting of this Fast Track designation is anticipated to accelerate its subsequent development and the process of obtaining market approval, thereby bringing benefits to patients across the globe at an earlier stage.